Pharmaceutical composition utilizing pancreatic beta cell proliferation factor
AssigneeTokyo Institute of Technology
InventorsTakeshi Imai, Hiroshi Handa
Life of this patent
Estimating the term…
Abstract
Disclosed are a pharmaceutical composition, a screening method, and the like which use UDP-glucose glycoprotein glycosyl transferase 1 (UGGT1) or a gene encoding the same. UGGT1 has an extremely high proliferative activity compared to known pancreatic β-cell proliferation factors; thus, UGGT1 can act as a useful therapeutic agent for diabetes without any modification and is also useful as a target substance for the development of a new therapeutic agent for diabetes.
Claims8
A pharmaceutical composition comprising a vector for expressing UGGT1 gene.
A transgenic non-human animal, wherein UGGT1 gene is introduced thereinto and the gene is expressed.
A cell transformed with a vector in which a reporter gene is linked downstream of a promoter of UGGT1 gene.
A screening method for a preventive agent or a therapeutic agent for diabetes, comprising the steps of mixing each test substance with UGGT1 and selecting test substances interacting with UGGT1;
- and administering each of the selected test substances to a non-human animal and selecting a test substance proliferating pancreatic β-cells in the non-human animal.
Dependencies are inferred from the claim text.